Matchpoint Therapeutics Raises $150M Series B Led by Nextech Invest for Covalent Immunology Drugs

Matchpoint Therapeutics Closes $150M Series B

Matchpoint Therapeutics, a Watertown, Massachusetts-based biotechnology company, has raised a $150 million Series B round. The round was led by Nextech Invest. The funding date is October 7, 2026.

What Matchpoint Therapeutics Does

Matchpoint Therapeutics focuses on the discovery of precision covalent medicines for autoimmune and inflammatory diseases. The company designs oral small molecules that selectively modulate disease-driving immune cell targets.

Its lead program, MPT-062, is an oral first-in-class T cell modulator. The company is advancing MPT-062 into clinical trials in 2027.

Investor Syndicate

The Series B included participation from a broad investor group:

• Nextech Invest (lead)
• Sanofi Ventures
• Invus
• The T1D Fund: A Breakthrough T1D Venture, LLC
• Digitalis Ventures
• Access Biotechnology
• Atlas Venture
• Bold Longevity Growth Fund
• Norwest Venture Partners
• BB Biotech

Acquisition Perspective

The Series B provides Matchpoint Therapeutics with capital as it advances MPT-062 toward clinical trials in 2027. For acquirers in immunology and inflammation, the company offers a precision covalent small-molecule platform and an oral first-in-class T cell modulator program. The presence of strategic and specialist life-science investors in the syndicate, including Sanofi Ventures, may be relevant to parties tracking the asset.

Round Details

• Company: Matchpoint Therapeutics
• Round: Series B
• Amount: $150,000,000 USD
• Date: October 7, 2026
• Lead investor: Nextech Invest
• Stage: Series B
• Headquarters: Watertown, Massachusetts
• Website: matchpointtx.com